YORK HOSPITAL
- Type
- Teaching hospital
- Where
- YORK, PA
- Medicare CCN
- 390046
- Received
- $445,830 in 336 records, 2019 ($119,907 general, $325,922 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: York Hospital Fuzzy (name and state)
- Nonprofit: YORK HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 38 | $119,907 |
| 2019 | Research payment | 298 | $325,922 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Edwards Lifesciences Corporation | 27 | $173,325 | 2019 |
| Stryker Corporation | 24 | $100,255 | 2019 |
| GW Research Limited | 7 | $57,033 | 2019 |
| Boehringer Ingelheim Pharma GmbH & Co.KG | 7 | $27,955 | 2019 |
| Boehringer Ingelheim International GmbH | 165 | $18,229 | 2019 |
| Merck Sharp & Dohme LLC | 7 | $13,200 | 2019 |
| Pharmacyclics LLC, an AbbVie Company | 69 | $10,850 | 2019 |
| TriReme Medical LLC | 4 | $10,750 | 2019 |
| Incyte Corporation | 2 | $8,690 | 2019 |
| Medical Device Business Services, Inc. | 2 | $7,375 | 2019 |
| Boston Scientific Corporation | 6 | $4,788 | 2019 |
| KARL STORZ Endoscopy-America | 3 | $3,240 | 2019 |
| Bolton Medical Inc | 4 | $2,100 | 2019 |
| Abbott Laboratories | 3 | $2,100 | 2019 |
| Medline Industries LP | 1 | $2,000 | 2019 |
| Masimo Corporation | 2 | $1,766 | 2019 |
| Zimmer Biomet Holdings, Inc. | 1 | $1,300 | 2019 |
| Amgen Inc. | 1 | $500 | 2019 |
| Olympus America Inc. | 1 | $370 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 298 | $325,922 |
| Gift | 11 | $98,335 |
| Grant | 5 | $10,475 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 16 | $5,159 |
| Education | 3 | $2,137 |
| Charitable Contribution | 1 | $2,000 |
| Space rental or facility fees (teaching hospital only) | 2 | $1,800 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Stryker Corporation | $16,451 | Gift | In-kind items and services | ISOFLEX SE Device, PATIENT HANDLING - PH | 2019 | |
| 2019-12-31 | Stryker Corporation | $16,185 | Gift | In-kind items and services | ISOFLEX SE Device, PATIENT HANDLING - PH | 2019 | |
| 2019-12-31 | Stryker Corporation | $16,185 | Gift | In-kind items and services | ISOFLEX SE Device, PATIENT HANDLING - PH | 2019 | |
| 2019-12-31 | Stryker Corporation | $16,185 | Gift | In-kind items and services | ISOFLEX SE Device, PATIENT HANDLING - PH | 2019 | |
| 2019-12-31 | Stryker Corporation | $7,614 | Gift | In-kind items and services | ISOFLEX LAL Device, PATIENT CARE - PC | 2019 | |
| 2019-12-31 | Stryker Corporation | $7,491 | Gift | In-kind items and services | ISOFLEX LAL Device, PATIENT CARE - PC | 2019 | |
| 2019-12-31 | Stryker Corporation | $7,491 | Gift | In-kind items and services | ISOFLEX LAL Device, PATIENT CARE - PC | 2019 | |
| 2019-12-31 | Stryker Corporation | $7,491 | Gift | In-kind items and services | ISOFLEX LAL Device, PATIENT CARE - PC | 2019 | |
| 2019-12-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $5,591 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-12-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,049 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-12-31 | Masimo Corporation | $1,742 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2019 | |
| 2019-12-19 | Edwards Lifesciences Corporation | $22,035 | Research payment | Cash or cash equivalent | PARTNER3 2015-08 | 2019 | |
| 2019-12-16 | Edwards Lifesciences Corporation | $6,969 | Research payment | Cash or cash equivalent | Early-TAVR Trial 2016-07 | 2019 | |
| 2019-12-13 | GW Research Limited | $6,837 | Research payment | Cash or cash equivalent | GWEP1415 | 2019 | |
| 2019-12-11 | Edwards Lifesciences Corporation | $4,011 | Research payment | Cash or cash equivalent | PARTNER3 2015-08 | 2019 | |
| 2019-12-11 | Abbott Laboratories | $900 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | 2019 | |
| 2019-12-11 | Boehringer Ingelheim International GmbH | $858 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-12-10 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-12-10 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-12-10 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-12-10 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-12-10 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-12-10 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-12-06 | GW Research Limited | $4,426 | Research payment | Cash or cash equivalent | GWEP1521 | 2019 | |
| 2019-12-06 | Boehringer Ingelheim International GmbH | $52 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-12-03 | Boehringer Ingelheim International GmbH | $858 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-12-03 | Boehringer Ingelheim International GmbH | $831 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-12-03 | Bolton Medical Inc | $550 | Research payment | Cash or cash equivalent | Treovance Phase II Trial Device | Treovance Phase II Trial | 2019 |
| 2019-12-03 | Bolton Medical Inc | $550 | Research payment | Cash or cash equivalent | Treovance Phase II Trial Device | Treovance Phase II Trial | 2019 |
| 2019-12-03 | Bolton Medical Inc | $500 | Research payment | Cash or cash equivalent | Treovance Phase II Trial Device | Treovance Phase II Trial | 2019 |
| 2019-11-29 | Edwards Lifesciences Corporation | $5,803 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2019 | |
| 2019-11-21 | GW Research Limited | $40,604 | Research payment | Cash or cash equivalent | GWEP1415 | 2019 | |
| 2019-11-18 | Boehringer Ingelheim International GmbH | $336 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-11-13 | TriReme Medical LLC | $500 | Research payment | Cash or cash equivalent | BALLOON CATHETER Device, BALLOON CATHETER | BALLOON CATHETER | 2019 |
| 2019-11-12 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-11-12 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-11-12 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-11-12 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-11-12 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-11-12 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-11-12 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-11-12 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-11-12 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $53 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $52 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $41 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $31 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $31 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $26 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $24 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $23 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $17 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $13 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-11-04 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-11-01 | Medical Device Business Services, Inc. | $3,375 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-10-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,049 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-10-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,049 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-10-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-10-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-10-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-10-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-10-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-10-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-10-18 | Edwards Lifesciences Corporation | $6,600 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | PARTNER II 2010-12 | 2019 |
| 2019-10-17 | Edwards Lifesciences Corporation | $14,803 | Research payment | Cash or cash equivalent | Early-TAVR Trial 2016-07 | 2019 | |
| 2019-10-09 | Stryker Corporation | $1,113 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $278 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $101 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $27 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-02 | Boehringer Ingelheim International GmbH | $831 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-10-02 | Boehringer Ingelheim International GmbH | $81 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-10-02 | Boehringer Ingelheim International GmbH | $29 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-09-25 | Boston Scientific Corporation | $900 | Grant | Cash or cash equivalent | GENERAL - STRUCTURAL HEART Device, STRUCTURAL HEART | 2019 | |
| 2019-09-23 | Edwards Lifesciences Corporation | $4,570 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2019 | |
| 2019-09-18 | Edwards Lifesciences Corporation | $1,014 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | Early-TAVR Trial 2016-07 | 2019 |
| 2019-09-18 | Edwards Lifesciences Corporation | $900 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | 2019 | |
| 2019-09-18 | Boston Scientific Corporation | $900 | Grant | Cash or cash equivalent | GENERAL - THERAPIES Device, THERAPIES | 2019 | |
| 2019-09-13 | Boston Scientific Corporation | $638 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2019 |
| 2019-09-11 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-09-11 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-09-11 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-09-11 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-09-10 | Boehringer Ingelheim International GmbH | $81 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-09-04 | Edwards Lifesciences Corporation | $1,214 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | PARTNER3 2015-08 | 2019 |
| 2019-09-04 | Edwards Lifesciences Corporation | $200 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | PARTNER3 2015-08 | 2019 |
| 2019-09-04 | Boehringer Ingelheim International GmbH | $23 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-09-04 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-09-04 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-09-04 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-08-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $2,541 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-30 | Edwards Lifesciences Corporation | $1,014 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | PARTNER3 2015-08 | 2019 |
| 2019-08-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-08-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-08-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-08-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-08-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-08-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-08-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-08-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-08-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-08-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-08-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-08-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-08-21 | Edwards Lifesciences Corporation | $500 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | PARTNER3 2015-08 | 2019 |
| 2019-08-09 | GW Research Limited | $300 | Research payment | Cash or cash equivalent | GWEP1415 | 2019 | |
| 2019-08-05 | Boehringer Ingelheim International GmbH | $81 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $41 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $30 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $30 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $30 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $30 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $26 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $26 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $25 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $25 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $24 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $12 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-07-31 | Edwards Lifesciences Corporation | $1,014 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | Early-TAVR Trial 2016-07 | 2019 |
| 2019-07-29 | Edwards Lifesciences Corporation | $226 | Research payment | Cash or cash equivalent | PARTNER II 2010-12 | 2019 | |
| 2019-07-29 | Edwards Lifesciences Corporation | $132 | Research payment | Cash or cash equivalent | PARTNER II 2010-12 | 2019 | |
| 2019-07-25 | Boehringer Ingelheim International GmbH | $52 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-07-23 | Boehringer Ingelheim International GmbH | $52 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-07-23 | Boehringer Ingelheim International GmbH | $52 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-07-23 | Boehringer Ingelheim International GmbH | $52 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-07-23 | Boehringer Ingelheim International GmbH | $17 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-07-19 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-07-19 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-07-19 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-07-19 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-07-17 | Edwards Lifesciences Corporation | $1,169 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | PARTNER II 2010-12 | 2019 |
| 2019-07-16 | KARL STORZ Endoscopy-America | $1,230 | Gift | In-kind items and services | CORD,HIGH FREQUENCY,BIPOLAR. Device, OTHER MISC | 2019 | |
| 2019-07-16 | Stryker Corporation | $758 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $246 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $95 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $19 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-11 | Edwards Lifesciences Corporation | $12,369 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2019 | |
| 2019-07-08 | Boehringer Ingelheim International GmbH | $858 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-07-08 | Boehringer Ingelheim International GmbH | $785 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-07-08 | Boehringer Ingelheim International GmbH | $81 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-07-02 | Zimmer Biomet Holdings, Inc. | $1,300 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-07-02 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | ABSORB Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2019 |
| 2019-07-02 | Boehringer Ingelheim International GmbH | $62 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-07-02 | Boehringer Ingelheim International GmbH | $31 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-07-02 | Boehringer Ingelheim International GmbH | $31 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-07-02 | Boehringer Ingelheim International GmbH | $26 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-07-02 | Boehringer Ingelheim International GmbH | $15 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-07-02 | Boehringer Ingelheim International GmbH | $15 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-07-02 | Boehringer Ingelheim International GmbH | $13 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-07-02 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-07-02 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-07-02 | Boehringer Ingelheim International GmbH | $7 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-06-24 | Edwards Lifesciences Corporation | $70,568 | Research payment | Cash or cash equivalent | PARTNER3 2015-08 | 2019 | |
| 2019-06-21 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-06-21 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-06-21 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-06-14 | Boston Scientific Corporation | $1,025 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2019 |
| 2019-06-13 | Boehringer Ingelheim International GmbH | $141 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-06-13 | Boehringer Ingelheim International GmbH | $59 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-06-13 | Boehringer Ingelheim International GmbH | $17 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-06-12 | Boehringer Ingelheim International GmbH | $796 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-06-12 | Boehringer Ingelheim International GmbH | $724 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-06-07 | Abbott Laboratories | $700 | Research payment | Cash or cash equivalent | ABSORB Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2019 |
| 2019-06-07 | Bolton Medical Inc | $500 | Research payment | Cash or cash equivalent | Treovance Phase II Trial Device | Treovance Phase II Trial | 2019 |
| 2019-06-07 | Merck Sharp & Dohme LLC | $300 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-06-04 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-06-04 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-06-04 | Boehringer Ingelheim International GmbH | $0 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-06-03 | TriReme Medical LLC | $250 | Research payment | Cash or cash equivalent | BALLOON CATHETER Device, BALLOON CATHETER | BALLOON CATHETER | 2019 |
| 2019-05-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,099 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-05-20 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-05-20 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-05-20 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-05-20 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-05-20 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-05-20 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-05-17 | KARL STORZ Endoscopy-America | $1,950 | Gift | In-kind items and services | SCISSORS,HORIZ CUT,RIGHT,SNGL Device, GYNECOLOGY | 2019 |
The latest 200 records of 336.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In York, PA, county York County, PA, state Pennsylvania; placed by its city name.
| Measure | Place (city or town) York, PA | County York County, PA | State Pennsylvania |
|---|---|---|---|
| Population B01003 | 44,938 | 462,924 | 13,018,639 |
| Population, 2020 census P1 | 44,800 | 456,438 | 13,002,700 |
| Median age B01002 | 34.3 | 41.1 | 40.9 |
| Under 18 B01001 | 23.9% | 21.9% | 20.4% |
| 65 and over B01001 | 13.1% | 18.8% | 19.5% |
| Households B11001 | 17,893 | 181,583 | 5,274,853 |
| Foreign born B05002 | 11.1% | 4.1% | 7.7% |
| Median household income B19013 | $48,420 | $84,829 | $77,971 |
| Median family income B19113 | $54,727 | $102,186 | $100,262 |
| Per capita income B19301 | $26,308 | $41,601 | $44,355 |
| Poverty rate B17001 | 21.1% | 8.4% | 11.7% |
| Unemployment rate B23025 | 10.7% | 4.5% | 5.3% |
| Civilian labor force B23025 | 23,179 | 245,693 | 6,684,175 |
| Mean commute (minutes) B08013 | 23.1 | 26.3 | 26.3 |
| Bachelor's degree or higher B15003 | 17.5% | 27.6% | 35.2% |
| Housing units B25001 | 19,505 | 189,857 | 5,806,452 |
| Owner-occupied B25003 | 43.7% | 76.3% | 69.3% |
| Renters B25003 | 56.3% | 23.7% | 30.7% |
| Median home value B25077 | $119,700 | $248,600 | $254,500 |
| Median gross rent B25064 | $1,014 | $1,193 | $1,209 |
| White, not Hispanic B03002 | 33.6% | 78.9% | 73.0% |
| Black B03002 | 24.1% | 5.8% | 10.3% |
| Hispanic or Latino B03002 | 36.6% | 9.6% | 8.7% |
| Asian B03002 | 1.0% | 1.5% | 3.8% |
| American Indian and Alaska Native B03002 | 0.0% | 0.0% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in York, PA.
Comments